Distinct characteristics of initiation of the classical and alternative complement pathways by Candida albicans.
Candida albicans is a potent activator of the complement system. The objective of this study was to characterize factors that influence the kinetics for activation of C3 and binding of C3 fragments to C. albicans. Factors that were examined included the surface properties of the yeast and contributions of the classical and alternative complement pathways. The results showed that incubation of hydrophobic, hydrophilic, or germinating yeast cells in normal human serum (NHS) containing radiolabeled C3 led to immediate accumulation of C3 on all three cell types, although the rate of accumulation of C3 on germinating cells was lower. An examination of the sites for early C3 binding showed that classical pathway initiation led to immediate, synchronous binding over the entire cell surface. A blockade of the classical pathway by absorption of putative classical pathway initiators or by chelation of calcium limited activation to the alternative pathway. Binding of C3 solely via the alternative pathway was characterized by a significant lag in the initial binding kinetics. In the absence of classical pathway initiation, the early cellular sites for C3 binding appeared as random, asynchronous foci of C3 that appeared to expand with time. The factor(s) mediating rapid deposition of C3 that was characteristic of the classical pathway initiation was reciprocally cross-absorbed by hydrophilic and hydrophobic C. albicans but was not removed by absorption of NHS with Saccharomyces cerevisiae, encapsulated Cryptococcus neoformans, or nonencapsulated C. neoformans. Delayed binding of C3 produced by absorption of serum was largely reversed by addition to the absorbed serum of immunoglobulin G isolated from NHS, indicating a significant role for a naturally occurring anti-C. albicans immunoglobulin C. in classical pathway initiation.
Kozel
T R
TR
Department of Microbiology and Cell and Molecular Biology Program, University of Nevada, Reno 89557, USA.
Weinhold
L C
LC
Lupan
D M
DM
D000908:Antibodies, Fungal / Q000276:immunology; D001665:Binding Sites; D001769:Blood / Q000276:immunology; D002176:Candida albicans / Q000254:growth & development / Q000276:immunology*; D003176:Complement C3 / Q000378:metabolism*; D003170:Complement Pathway, Alternative; D003171:Complement Pathway, Classical; D003455:Cryptococcus neoformans / Q000276:immunology; D006801:Humans; D007074:Immunoglobulin G / Q000276:immunology; D007700:Kinetics; D011485:Protein Binding; D012441:Saccharomyces cerevisiae / Q000276:immunology; D013045:Species Specificity
D000908:Antibodies, Fungal; D003176:Complement C3; D007074:Immunoglobulin G